TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02621294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measuring protein requirement
Description: a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
Study: NCT03270839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonine 25Mg Chewable Tablet
Description: Motion sickness drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonine 25Mg Chewable Tablet
Description: Motion sickness drug
Study: NCT02127970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin IV infusion over 30 minutes.
Study: NCT00881647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
Study: NCT01708135

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of smartphone app
Study: NCT01922791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of probiotics, fish oil and their combination to placebo
Description: Double-blind randomized placebo controlled intervention
Study: NCT01303601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Study: NCT03676907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double layer suturation technique
Description: in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
Study: NCT04010942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Tablet
Study: NCT03200678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic assessment
Description: muscle torque assessement
Study: NCT02127970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin IV infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin-matching Placebo
Description: Dalbavancin-matching placebo IV infusion over 30 minutes.
Study: NCT03200678

Intervention type: OTHER
Group type: OTHER
Intervention: isokinetic assessment
Description: muscle torque assessement
Study: NCT02045511

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study: NCT04380987

Intervention type: BIOLOGICAL
Intervention: Biological sampling
Description: For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
Study: NCT01814735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown rice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brown rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Study: NCT01054638

Intervention type: DRUG
Intervention: HAART Treatment
Description: Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.

Intervention type: DRUG
Intervention: HAART Treatment
Description: Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.
Study: NCT04427969

Intervention type: BEHAVIORAL
Intervention: prone position
Description: to lay in prone position at least 12 hour in a day at ICU
Study: NCT04278534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Complete radiation therapist-led education module using virtual reality
Study: NCT02935673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumicitabine
Description: Oral administration of lumicitabine as tablet.
Study: NCT04278534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive the usual verbal and written education materials
Study: NCT04278534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive the usual verbal and written education materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Complete radiation therapist-led face-to-face education module

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00472134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: On-Q PainBuster pump
Description: local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
Study: NCT01485523

Intervention type: OTHER
Intervention: Nasal provocation test
Description: TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.

Intervention type: OTHER
Intervention: Nasal provocation test
Description: TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Study: NCT00665184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise via Negative Eccentric Work
Description: High intensity resistance training delivered 2-3 times per week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care exercise training
Description: Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
Study: NCT00106782

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Electrical Polarization (TEP)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Electrical Polarization (TEP)
Study: NCT02346084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
Description: Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
Description: Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling).
Study: NCT02357940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: 1% Colloidal Oatmeal Balm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: 1% Colloidal Oatmeal Balm
Study: NCT01625247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical drainage
Description: Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical drainage
Description: Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
Study: NCT02625610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study: NCT02442778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-18
Description: 18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study: NCT02242851

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT02264002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine low dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine low dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine high dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine high dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03546751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
Study: NCT02935673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration of matching placebo.
Study: NCT02453269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdisciplinary program
Study: NCT03546751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet And Exercise
Description: This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
Study: NCT03137888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Escalated Radiation Therapy
Description: Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectroscopic Magnetic Resonance Imaging
Description: Patients will undergo sMRI scans within a 14 day window prior to starting treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04048642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH
Description: 7 days of a DASH diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-Food, Plant-Based
Description: 7 days of a WFPB diet
Study: NCT02653651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infused at 0.1 mg/kg/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine infused at 1 mg/kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of saline
Study: NCT00788827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ stem cells
Description: Up to 5 x 10 log 8 of autologous stem cells on a single occasion
Study: NCT02685631

Intervention type: OTHER
Intervention: Yttrium-90 Resin Microspheres
Description: Data collection into the RESIN registry
Study: NCT02800356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthreshold 577 nm yellow wavelength laser photo-coagulator
Description: Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthreshold 577 nm yellow wavelength laser photo-coagulator
Description: Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management.
Study: NCT01297907

Intervention type: OTHER
Intervention: Methacholine Challenge Test
Description: Methacholine challenge test to evaluate airway hyperreactivity
Study: NCT03681067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- sodium chloride
Description: Placebo injectable solution will be delivered via intravenous infusion as a single infusion
Study: NCT01297907

Intervention type: OTHER
Intervention: Methacholine Challenge Test
Description: Methacholine challenge test to evaluate airway hyperreactivity

Intervention type: OTHER
Intervention: Fractional Exhaled NO (FENO)
Description: Fractional Exhaled NO to evaluate eosinophilic inflammation

Intervention type: OTHER
Intervention: Fractional Exhaled NO (FENO)
Description: Fractional Exhaled NO to evaluate eosinophilic inflammation

Intervention type: OTHER
Intervention: Blood Test
Description: Blood Tests (Eosinophil Count)

Intervention type: OTHER
Intervention: PCDAI
Description: Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
Study: NCT01120756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-oriented attentional self-regulation
Description: This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.